Ponatinib: Multi-Target TKI for CML & Ph+ ALL
Ponatinib is a potent, third-generation, multi-targeted tyrosine kinase inhibitor (TKI) primarily designed to inhibit the BCR-ABL oncoprotein. It was specifically engineered to overcome resistance caused by the T315I gatekeeper mutation — the most common mutation conferring resistance to other BCR-ABL inhibitors such as imatinib, dasatinib, and nilotinib.
In addition to BCR-ABL, ponatinib inhibits multiple other kinases including VEGFR, PDGFR, FGFR, EPH receptors, and SRC family kinases, providing a broad anti-tumor activity profile. On Unifarm, you can find details regarding original medications (such as Iclusig) containing this active ingredient.
Indications
- Chronic Myeloid Leukemia (CML): Treatment of adult patients with chronic phase, accelerated phase, or blast phase CML harboring the T315I mutation, or for whom no other TKI therapy is appropriate due to resistance or intolerance to at least two prior TKIs.
- Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Treatment of adult patients with Ph+ ALL harboring the T315I mutation, or for whom no other TKI therapy is appropriate due to resistance or intolerance to at least two prior TKIs.
Dosage and administration
Available as film-coated tablets. Taken orally once daily.
Standard Regimen:
- Recommended Starting Dose: 45 mg orally once daily.
- Administration: Swallow tablets whole with water. May be taken with or without food. Do not crush or break tablets.
- Dose Reduction: Upon achieving a response or for management of adverse reactions, the dose may be reduced to 30 mg or 15 mg once daily.
Blood pressure, hepatic and pancreatic function, and complete blood counts should be monitored before and regularly during treatment. Dose adjustments may be necessary when co-administered with strong CYP3A4 inhibitors or inducers.
- Hypersensitivity to ponatinib or any excipient.
- Pregnancy and breastfeeding (can cause fetal harm).
- Uncontrolled hypertension.
- History of serious arterial occlusive events (benefit-risk must be carefully assessed).
- Active pancreatitis.
Ponatinib requires careful monitoring due to its significant safety profile. Regular cardiovascular assessment and blood tests are essential. Common adverse reactions include:
- Cardiovascular: Arterial occlusive events (myocardial infarction, stroke, peripheral arterial stenosis) — serious, dose-dependent risk; hypertension (very common).
- Hematologic: Thrombocytopenia, neutropenia, anemia, leukopenia (very common, may be severe).
- Gastrointestinal: Abdominal pain, nausea, constipation, pancreatitis (including lipase elevation).
- Hepatic: Elevated liver enzymes (ALT, AST), hepatotoxicity.
- Dermatologic: Rash, dry skin.
- General: Fatigue, headache, arthralgia, myalgia, pyrexia.
- Venous thromboembolism: Deep vein thrombosis, pulmonary embolism.
